Pharmaceutical
- Pharmaceutical intermediates
- Heterocyclic Compound
- OLED material intermediate
- Diphenylamine intermediates
- Nutritional Supplements
- Pharmaceutical raw materials
Human APIs Powder
- Respiratory Drugs Raw Material
- Antiviral Antibacterial
- Antipyretic Analgesics
- Antihistamine Drugs
- Antineoplastic
- Urinary System Drugs
- Endocrine System
- Other
Medicine Excipients
Veterinary raw materials
Phone: 86-29-89601602
E-mail: sales21@interlgroup.com
Add: Fengcheng 2nd Road, Weiyang District, Xi'an, Shaanxi, China
dexibuprofen Raw Materials Powder
Product Overview:
Dexibuprofen is the dextrose form of ibuprofen. It has been found that the pharmacological activity of ibuprofen is mainly derived from the dextrose form, and that it has a higher efficacy than the equivalent dose of ibuprofen, with therapeutic effects being achieved with smaller doses.
dexibuprofen Raw Materials Powder Attributes
CAS:51146-56-6
MF: C13H18O2
MW: 206.28
EINECS: 610-620-9
Specification: 99% min dexibuprofen Powder
Sample: dexibuprofen Powder
Packaging:1kg/bag, 25kg/drum
Brand: Henrikang
Appearance: White Powder
Storage: Cool Dry Place
Shelf Life: 2 Years
Test Method: HPLC
dexibuprofen Raw Materials Powder Details
dexibuprofen Raw Powder Usage and Synthesis.
There is an isomerase (2-arylpropionyl-CoA epimerase) in the body that converts (R)-isobutylpropionic acid to (S)-(+)-isobutylpropionic acid. Because of this, and because of the high cost of synthesising compounds with special optical selectivity, only racemic products are currently on the market. Dextro Ibuprofen is the right-handed form of Ibuprofen, a non-steroidal antipyretic, analgesic, and anti-inflammatory drug, and the right-handed form is more potent than the racemic and levitra forms. In the body, 60% of the levosome, can be converted to the dextrosome, for for the overall level of the drug to provide an active reserve.
Uses and functions of dexibuprofen Powder.
Antipyretic and analgesic anti-inflammatory drugs.
Pharmacological dexibuprofen Raw Materials Powder.
(S)-(+)-Ibuprofen(HCT-15andHCA-7cells;0-1000µM;8days)treatmentreducesconcentrationdependentlycellsurvivalinbothcelllinestoasimilarextent.(S)-(+)-Ibuprofen(HCT-15andHCA-7cells;0-1000µM;20-72hours)treatmentcausesaG0/G1phaseblockaswellasapoptosis.(S)-(+)-Ibuprofen(HCT-15andHCA-7cells;9Chemicalbook00µM;4-72hours)treatmentshowsadownregulationofcyclinAandBandanincreaseofthecellcycleinhibitoryproteinp27Kip-1.(S)-(+)-IbuprofeninhibitsCOXactivity,thromboxaneformation,andplateletaggregation.(S)-(+)-IbuprofeninhibitstheactivationofNF-κBinresponsetoT-cellstimulationwithanIC50of61.7μM.
